Cas no 94415-42-6 (4-Chloro-6-hydrazinyl-2-isobutylpyrimidine)

4-Chloro-6-hydrazinyl-2-isobutylpyrimidine is a versatile pyrimidine derivative with significant utility in organic synthesis and pharmaceutical research. Its reactive hydrazinyl and chloro substituents make it a valuable intermediate for constructing heterocyclic compounds, particularly in the development of biologically active molecules. The isobutyl group enhances lipophilicity, potentially improving membrane permeability in drug design applications. This compound is particularly useful in nucleophilic substitution and condensation reactions, enabling the synthesis of pyrazolo[3,4-d]pyrimidines and other fused heterocycles. Its stability under standard conditions and well-defined reactivity profile facilitate controlled modifications, making it a reliable building block for medicinal chemistry and agrochemical research.
4-Chloro-6-hydrazinyl-2-isobutylpyrimidine structure
94415-42-6 structure
Product Name:4-Chloro-6-hydrazinyl-2-isobutylpyrimidine
CAS No:94415-42-6
MF:C8H13ClN4
MW:200.66861987114
CID:3168107
PubChem ID:119081597
Update Time:2025-05-22

4-Chloro-6-hydrazinyl-2-isobutylpyrimidine Chemical and Physical Properties

Names and Identifiers

    • 94415-42-6
    • 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine
    • Inchi: 1S/C8H13ClN4/c1-5(2)3-7-11-6(9)4-8(12-7)13-10/h4-5H,3,10H2,1-2H3,(H,11,12,13)
    • InChI Key: KKPURDHGLZEEBO-UHFFFAOYSA-N
    • SMILES: ClC1C=C(NN)N=C(CC(C)C)N=1

Computed Properties

  • Exact Mass: 200.0828741Da
  • Monoisotopic Mass: 200.0828741Da
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 13
  • Rotatable Bond Count: 3
  • Complexity: 153
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 2.4
  • Topological Polar Surface Area: 63.8?2

4-Chloro-6-hydrazinyl-2-isobutylpyrimidine Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Alichem
A089005667-5g
4-Chloro-6-hydrazinyl-2-isobutylpyrimidine
94415-42-6 97%
5g
$1624.08 2023-08-31
Alichem
A089005667-10g
4-Chloro-6-hydrazinyl-2-isobutylpyrimidine
94415-42-6 97%
10g
$2653.20 2023-08-31
Alichem
A089005667-25g
4-Chloro-6-hydrazinyl-2-isobutylpyrimidine
94415-42-6 97%
25g
$3714.48 2023-08-31

4-Chloro-6-hydrazinyl-2-isobutylpyrimidine Related Literature

Additional information on 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine

Recent Advances in the Study of 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine (CAS: 94415-42-6)

The compound 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine (CAS: 94415-42-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential.

Recent studies have highlighted the role of 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine as a key intermediate in the synthesis of novel pyrimidine derivatives. Pyrimidine-based compounds are known for their diverse pharmacological properties, including antimicrobial, antiviral, and anticancer activities. The hydrazinyl and chloro functional groups in this compound make it a versatile building block for further chemical modifications.

One of the most notable advancements is the use of 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine in the development of kinase inhibitors. Kinases are critical targets in cancer therapy, and recent research has demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific kinase isoforms. For instance, a study published in the Journal of Medicinal Chemistry reported the synthesis of a series of pyrimidine-based inhibitors using 94415-42-6 as a starting material, showing promising results in preclinical models of breast cancer.

In addition to its role in kinase inhibition, 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine has been explored for its antimicrobial properties. A recent study in the European Journal of Medicinal Chemistry demonstrated that hydrazinylpyrimidine derivatives exhibit significant activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve interference with bacterial cell wall synthesis, making these compounds potential candidates for addressing antibiotic resistance.

The synthetic pathways for 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine have also been optimized in recent years. Researchers have developed more efficient and scalable methods for its production, reducing the cost and environmental impact of synthesis. For example, a green chemistry approach utilizing microwave-assisted synthesis has been reported to yield high purity 94415-42-6 with reduced reaction times and solvent use.

Despite these promising developments, challenges remain in the clinical translation of 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine derivatives. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further structure-activity relationship (SAR) studies and medicinal chemistry optimization. Ongoing research is focused on improving the pharmacokinetic properties of these compounds to enhance their therapeutic potential.

In conclusion, 4-Chloro-6-hydrazinyl-2-isobutylpyrimidine (CAS: 94415-42-6) represents a valuable scaffold in medicinal chemistry with diverse applications in drug discovery. Recent studies have underscored its potential in kinase inhibition and antimicrobial therapy, while advances in synthetic methodologies have improved its accessibility. Future research should focus on overcoming the current limitations to fully realize its therapeutic benefits.

Recommended suppliers
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
PRIBOLAB PTE.LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
PRIBOLAB PTE.LTD
Changzhou Guanjia Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Changzhou Guanjia Chemical Co., Ltd
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SHOCHEM(SHANGHAI) CO.,lTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SHOCHEM(SHANGHAI) CO.,lTD